Filbrandt Wealth Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Filbrandt Wealth Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-150	Closed	-$1K	–	482
2020 Q1	$1K	Buy	+150	New	+$646	﹤0.01%	244

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Filbrandt Wealth Management's PGNX Position: Q2 2020 in Review

Filbrandt Wealth Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 150 shares — an estimated $1K sold.

Filbrandt Wealth Management first reported a position in PGNX in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Filbrandt Wealth Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Filbrandt Wealth Management sold 150 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1K.
Filbrandt Wealth Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2020 and held it in 1 quarter.
Filbrandt Wealth Management's Progenics Pharmaceuticals Inc position peaked at $1K in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Filbrandt Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.